The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines.

Abstract:

BACKGROUND:Cardiac toxicity from anthracyclines (ACH) can lead to therapy discontinuation, hospitalization or congestive heart failure (CHF). Since such risk may vary by patient, we developed and tested a risk-prediction tool for cardiac toxicity in metastatic breast cancer (MBC) patients receiving chemotherapy with doxorubicin, either in its traditional (DOX) or pegylated liposomal (PLD) formulation. METHODS:Data was obtained (n = 509) from a randomized clinical trial of MBC patients assigned either DOX (60 mg/m(2) every 3 weeks) or PLD (50 mg/m(2) every 4 weeks) (O'Brien Ann Oncol 15, 440-449, 2004). Patient, disease and treatment factors were identified for each cycle of therapy. Factors with a P-value of or=grade 2 cardiac toxicity following a cycle were retained and included in a generalized estimating equations (GEE) regression model A risk scoring algorithm (range 0-62) was then developed from the final model. RESULTS:Factors predictive of cardiac toxicity included an interaction effect between DOX and the number of cumulative cycles, patient age and weight, previous ACH exposure and poor performance status. A ROC analysis had an area under the curve (AUC) of 0.84 (95% CI: 0.79-0.89). A precycle risk score cutoff of >or=30 to <40 was identified to optimally balance sensitivity (58.5%) and specificity (89.0%). Patients with a score in a given cycle, within or above this threshold, would be considered at high risk for cardiac toxicity. CONCLUSION:Our model provides patient specific risk information that could be helpful in assessing the risks and benefits of anthracyclines in the MBC patients.

authors

Dranitsaris G,Rayson D,Vincent M,Chang J,Gelmon K,Sandor D,Reardon G

doi

10.1007/s10549-007-9803-5

subject

Has Abstract

pub_date

2008-02-01 00:00:00

pages

443-50

issue

3

eissn

0167-6806

issn

1573-7217

journal_volume

107

pub_type

杂志文章
  • Adeno-associated virus-mediated expression of recombinant CBD-HepII polypeptide of human fibronectin inhibits metastasis of breast cancer.

    abstract::CH50, a recombinant CBD-HepII polypeptide of human fibronectin, was shown to suppress tumor metastasis in murine hepatocarcinoma and melanoma models. However, the effect of CH50 on human cancer cells is still not clear. Here we evaluated the efficiency of CH50 delivered by recombinant adeno-associated virus (rAAV) vec...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-013-2783-8

    authors: He ZH,Lei Z,Zhen Y,Gong W,Huang B,Yuan Y,Zhang GM,Wang XJ,Feng ZH

    更新日期:2014-01-01 00:00:00

  • Accuracy of fine needle aspiration cytology (FNAC) of axillary lymph nodes as a triage test in breast cancer staging.

    abstract:INTRODUCTION:Axillary node fine needle aspiration cytology (FNAC) has the potential to triage women with operable breast cancer to initial nodal surgical procedure. Because of variability in the reported accuracy of this test its role and clinical utility in pre-operative staging remains controversial. METHODS:We retr...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-006-9355-0

    authors: Ciatto S,Brancato B,Risso G,Ambrogetti D,Bulgaresi P,Maddau C,Turco P,Houssami N

    更新日期:2007-05-01 00:00:00

  • A two-stage approach to genetic risk assessment in primary care.

    abstract::Genetic risk prediction models such as BRCAPRO are used routinely in genetic counseling for identification of potential BRCA1 and BRCA2 mutation carriers. They require extensive information on the counselee and her family history, and thus are not practical for primary care. To address this gap, we develop and test a ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-016-3686-2

    authors: Biswas S,Atienza P,Chipman J,Blackford AL,Arun B,Hughes K,Parmigiani G

    更新日期:2016-01-01 00:00:00

  • EGF binding is quantitatively related to growth in node-positive breast cancer.

    abstract::Number of mitoses and EGF binding were determined in parallel in biopsies of 27 lymph-node positive and of 23 lymph-node negative breast cancer patients. For node-positive patients the parameters for cell growth and EGF binding were quantitatively correlated by the equation y = P3 + P1(1- exp(- P2x]. For node-negative...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01805739

    authors: Spitzer E,Koepke K,Kunde D,Grosse R

    更新日期:1988-09-01 00:00:00

  • Analysis of breast cancer in young women in the Department of Defense (DOD) database.

    abstract:PURPOSE:Breast tumors from young women under the age of 40 account for approximately 7% of cases and have a poor prognosis independent of established prognostic factors. We evaluated the patient population served by the Military Health System, where a disproportionate number of breast cancer cases in young women are se...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4615-8

    authors: Zimmer AS,Zhu K,Steeg PS,Wu A,Gatti-Mays ME,Soltani S,Perkins JG,Shao S,Brown D,Georg M,Hu H,Shriver CD,Lipkowitz S

    更新日期:2018-04-01 00:00:00

  • A phase II trial of tamoxifen, premarin, methotrexate and 5-fluorouracil in metastatic breast cancer.

    abstract::Complete remissions in patients with metastatic breast cancer using endocrine therapy or chemotherapy are infrequent. Breast tumors are known to be heterogeneous with respect to estrogen receptor status, and the low complete remission rate may be related to this biochemical heterogeneity. Based on laboratory experimen...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01805721

    authors: Allegra JC,Woodcock TM,Richman SP,Bland KI,Wittliff JL

    更新日期:1982-01-01 00:00:00

  • Breast cancer expresses functional NMDA receptors.

    abstract::We demonstrate here that functional NMDAR1 and NMDAR2 receptors are expressed by Mcf-7 and SKBR3 breast cancer cell lines, and possibly by most or all high-grade breast tumors, and that these receptors are important for the growth of human breast cancer xenografts in mice. RT-PCR demonstrated mRNA for both NMDAR1 and ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-009-0556-1

    authors: North WG,Gao G,Memoli VA,Pang RH,Lynch L

    更新日期:2010-07-01 00:00:00

  • Tamoxifen as initial endocrine therapy for metastatic breast cancer: long term follow-up of two Piedmont Oncology Association (POA) trials.

    abstract:PURPOSE:To examine the outcomes of endocrine naive patients treated with tamoxifen as initial endocrine therapy for metastatic breast cancer. Data were obtained from the long-term follow-up of two previously published randomized trials. PATIENTS AND METHODS:All patients received tamoxifen 20 mg po in a single daily do...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1023/a:1005758127114

    authors: Kuss JT,Muss HB,Hoen H,Case LD

    更新日期:1997-02-01 00:00:00

  • Natural helping functions of lay health advisors in breast cancer education.

    abstract::The Save Our Sisters Project builds on the roles of 95 "natural helpers" to increase mammography screening among older African American women in a NC county. Natural helpers are lay people to whom others naturally turn for advice, emotional support, and tangible aid. Findings from 14 focus group interviews showed that...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF00694741

    authors: Eng E,Smith J

    更新日期:1995-07-01 00:00:00

  • Oestrogen and progesterone receptor content and the distribution of histological grade in breast cancer.

    abstract::Histological grading of 160 primary infiltrating breast carcinomas showed that both oestrogen and progesterone receptor status are strongly related to grade, tumours that are receptor positive tending to be of lower grade than the receptor negative. The nuclear factors used in grading were those that determined this a...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01806938

    authors: Thoresen S,Thorsen T,Tangen M,Hartveit F

    更新日期:1982-01-01 00:00:00

  • Neutrophil-to-lymphocyte ratio as a predictor of survival in patients with triple-negative breast cancer.

    abstract:PURPOSE:Peripheral blood lymphopenia and elevated neutrophil-to-lymphocyte ratio (NLR) have been associated with poor outcomes in various malignancies. However, existing literature has largely focused on baseline parameters. The aim of this study is to assess the impact of radiation therapy (RT) and chemotherapy on abs...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-018-05106-7

    authors: Patel DA,Xi J,Luo J,Hassan B,Thomas S,Ma CX,Campian JL

    更新日期:2019-04-01 00:00:00

  • Circulating CA 15-3 levels in the postsurgical follow-up of breast cancer patients and in non-malignant diseases.

    abstract::Circulating CA 15-3 antigen levels were evaluated in patients with benign diseases and breast cancer patients with no clinical evidence of disease after surgery (NED). Patients with breast cancer NED were followed for tumor recurrence or death during a median of 12.9 months (range 1 to 25 months). CA 15-3 and carcinoe...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01806524

    authors: Colomer R,Ruibal A,Genollá J,Rubio D,Del Campo JM,Bodi R,Salvador L

    更新日期:1989-03-01 00:00:00

  • Body mass index, age at breast cancer diagnosis, and breast cancer subtype: a cross-sectional study.

    abstract:PURPOSE:Evidence suggests that premenopausal obesity decreases and postmenopausal obesity increases breast cancer risk. Because it is not well known whether this is subtype dependent, we studied the association between body mass index (BMI) and age at breast cancer diagnosis, or the probability of being diagnosed with ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4579-8

    authors: Brouckaert O,Van Asten K,Laenen A,Soubry A,Smeets A,Nevelstreen I,Vergote I,Wildiers H,Paridaens R,Van Limbergen E,Weltens C,Moerman P,Floris G,Neven P,Multidisciplinary breast centre Leuven.

    更新日期:2018-02-01 00:00:00

  • Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel-FEC as primary therapy for HER2-positive breast cancer in everyday clinical practice.

    abstract::One of the most efficacious primary therapies in HER2-positive breast cancer was published by the M.D. Anderson group in 2005. This randomized trial evaluated the addition of trastuzumab to a taxane-anthracycline based chemotherapy. Despite largely significant differences in pathological complete response (pCR) in the...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章

    doi:10.1007/s10549-012-2149-7

    authors: Pernas S,Gil-Gil M,de Olza MO,Gumà A,Climent F,Petit A,Pla MJ,García-Tejedor A,López-Ojeda A,Falo C,Fernandez-Otega A,Mesia C,Pérez-Martin FJ,Urruticoechea A,Germà JR

    更新日期:2012-08-01 00:00:00

  • Mutation analysis of the SLX4/FANCP gene in hereditary breast cancer.

    abstract::SLX4 coordinates three structure-specific endonucleases in the DNA damage response. One subtype of Fanconi anaemia, FA-P, has recently been attributed to biallelic SLX4 gene mutations. To investigate whether monoallelic SLX4 gene defects play some role in the inherited component of breast cancer susceptibility, in thi...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1681-1

    authors: Landwehr R,Bogdanova NV,Antonenkova N,Meyer A,Bremer M,Park-Simon TW,Hillemanns P,Karstens JH,Schindler D,Dörk T

    更新日期:2011-12-01 00:00:00

  • A GINECO randomized phase II trial of two capecitabine and weekly paclitaxel schedules in metastatic breast cancer.

    abstract::To determine whether capecitabine schedule adaptation improves the tolerability of capecitabine-paclitaxel combination therapy for metastatic breast cancer (MBC), patients with anthracycline-pretreated HER2-negative MBC were randomized to either arm A (21-day cycles: capecitabine 1,000 mg/m(2) twice daily, days 1-14; ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s10549-011-1776-8

    authors: Lortholary A,Hardy-Bessard AC,Bachelot T,de Rauglaudre G,Alexandre J,Bourgeois H,Jaubert D,Paraiso D,Largillier R

    更新日期:2012-01-01 00:00:00

  • Clinical/genetic features in hereditary breast cancer.

    abstract::Patients from hereditary breast cancer-prone (HBC) families provide one of the most powerful and potentially cost effective models for cancer prevention and control. Paradoxically, this opportunity is often missed in the clinical practice setting due, in part, to inattention to the family history and/or lack of knowle...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01810778

    authors: Lynch HT,Watson P,Conway TA,Lynch JF

    更新日期:1990-02-01 00:00:00

  • Effects of toremifene (TOR) and tamoxifen (TAM) on serum lipids in postmenopausal patients with breast cancer.

    abstract::This study clarified the difference in the effects on serum lipids between toremifene (TOR) and tamoxifen (TAM). To remove influencing factors, we investigated adjuvant therapy for hormone receptor-positive patients with breast cancer without lymph node metastasis. The subjects were 65 patients who were enrolled in a ...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1007/s10549-004-4384-z

    authors: Kusama M,Miyauchi K,Aoyama H,Sano M,Kimura M,Mitsuyama S,Komaki K,Doihara H

    更新日期:2004-11-01 00:00:00

  • Knowledge and perceptions of familial and genetic risks for breast cancer risk in adolescent girls.

    abstract::Evidence suggests early events might modify adult breast cancer risk and many adolescents learn of familial and genetic risks for breast cancer. Little is known about how adolescent girls understand and respond to breast cancer risk. Semi-structured interviews with 11-19 year-old girls at high-risk and population-risk...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章

    doi:10.1007/s10549-012-2254-7

    authors: Bradbury AR,Patrick-Miller L,Egleston BL,Schwartz LA,Sands CB,Shorter R,Moore CW,Tuchman L,Rauch P,Malhotra S,Rowan B,Van Decker S,Schmidheiser H,Bealin L,Sicilia P,Daly MB

    更新日期:2012-12-01 00:00:00

  • Membrane proteases as potential diagnostic and therapeutic targets for breast malignancy.

    abstract::Metastasizing cancer cells can invade the extracellular matrix using plasma membrane protrusions, termed invadopodia, that contact and dissolve the matrix. Various membrane associated proteases localized on the invadopodial membranes are responsible for the extracellular matrix degradation. Work from our laboratory sh...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/BF00666155

    authors: Chen WT,Lee CC,Goldstein L,Bernier S,Liu CH,Lin CY,Yeh Y,Monsky WL,Kelly T,Dai M

    更新日期:1994-01-01 00:00:00

  • Overview of luteinizing hormone-releasing hormone agonists in early breast cancer-benefits of reversible ovarian ablation.

    abstract::Goserelin ('Zoladex'), a luteinizing hormone-releasing hormone (LHRH) agonist induces reversible ovarian ablation in premenopausal women. It is the most extensively studied LHRH agonist for the treatment of breast cancer and data from a large clinical trial program show that, alone or in combination with tamoxifen, go...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1023/a:1020309715942

    authors: Jonat W

    更新日期:2002-10-01 00:00:00

  • Autoradiographic localization of 3H-ORG 2058, a synthetic progestin, in the mammary glands of the baboon.

    abstract::The uptake and retention of a radiolabeled synthetic progestin ORG 2058 by the mammary glands were examined in the baboon. Four estrogen-primed baboons were injected intravenously with 2.5 micrograms/kg body weight of 3H-ORG 2058. One animal received an additional injection of 2.5 mg/kg body weight of unlabeled proges...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01806397

    authors: Weaker FJ,Sheridan PJ

    更新日期:1984-01-01 00:00:00

  • Diagnostic ability of different human milk fat globule antigens in breast cancer.

    abstract::Human mammary epithelial antigens (HME-Ags) are released into the circulation by breast tumors and not by normal breast tissue (Proc. Natl. Acad. Sci. USA 74: 582-586, 1977). This characteristic made them valuable, together with other breast cancer related antigens later identified, to develop immunoassays useful in t...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01806353

    authors: Ceriani RL,Blank EW,Rosenbaum EH,Ben Zeev D,Lowitz RS,Johansen L,Trujillo T

    更新日期:1990-05-01 00:00:00

  • Impact of self-reported data on the acquisition of multi-generational family history and lifestyle factors among women seen in a high-risk breast screening program: a focus on modifiable risk factors and genetic referral.

    abstract:BACKGROUND:The phrase "high-risk for breast cancer" is used to identify various groups at elevated cancer risk, and the appropriate surveillance and risk-reducing strategies differ based on the etiology of risk. Here, we review the utility of patient-reported data to capture women with modifiable lifestyle risk factors...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4115-x

    authors: Rosenberger LH,Weber R,Sjoberg D,Vickers AJ,Mangino DA,Morrow M,Pilewskie ML

    更新日期:2017-04-01 00:00:00

  • Tests for detecting recurrent disease in the follow-up of patients with breast cancer.

    abstract::In 141 postmenopausal node-positive patients with primary breast cancer, routine biochemical markers (alkaline phosphatase, gamma-glutamyl transpeptidase, carcinoembryonic antigen), and chest x-ray, in combination with history and clinical examination, have been performed at 3 monthly intervals for at least 2 years. S...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01807283

    authors: Mansi JL,Earl HM,Powles TJ,Coombes RC

    更新日期:1988-07-01 00:00:00

  • Dual HER2-targeted approaches in HER2-positive breast cancer.

    abstract::Approximately 15-20% of all breast cancers are human epidermal growth factor receptor 2 (HER2) positive, with clinical studies having validated the HER2 receptor tyrosine kinase pathway as an important therapeutic target. Presently, two HER2-targeted therapies are approved by the Food and Drug Administration for treat...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/s10549-011-1781-y

    authors: Ahn ER,Vogel CL

    更新日期:2012-01-01 00:00:00

  • Mammographic breast density decreases after bariatric surgery.

    abstract:PURPOSE:Breast density (BD), an important risk factor for breast cancer, can change over time in some women, but the underlying mechanism is unclear. Very little is known about the impact of surgical weight loss on BD. Our hypothesis is that weight loss after bariatric surgery is associated with a significant and favor...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4361-y

    authors: Williams AD,So A,Synnestvedt M,Tewksbury CM,Kontos D,Hsiehm MK,Pantalone L,Conant EF,Schnall M,Dumon K,Williams N,Tchou J

    更新日期:2017-10-01 00:00:00

  • Desferri-exochelin induces death by apoptosis in human breast cancer cells but does not kill normal breast cells.

    abstract::A major goal of cancer chemotherapy is the identification of cytotoxic compounds that are highly selective for cancer cells. We describe here one such compound - a novel iron chelator, desferri-exochelin 772SM. This desferri-exochelin has unique chemical and pharmacological properties, including extremely high iron bi...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1012211828319

    authors: Pahl PM,Horwitz MA,Horwitz KB,Horwitz LD

    更新日期:2001-09-01 00:00:00

  • The prognostic impact of age in different molecular subtypes of breast cancer.

    abstract::Breast cancer is a heterogeneous entity composed of distinct molecular subgroups with different molecular and clinical features. We analyzed the association between molecular breast cancer subgroups, age at diagnosis, and prognosis in a compilation of publicly available gene expression datasets. Affymetrix gene expres...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-015-3491-3

    authors: Liedtke C,Rody A,Gluz O,Baumann K,Beyer D,Kohls EB,Lausen K,Hanker L,Holtrich U,Becker S,Karn T

    更新日期:2015-08-01 00:00:00

  • Thrombocytosis as a prognostic factor in inflammatory breast cancer.

    abstract:PURPOSE:Platelets are essential components of hemostasis and also play an important role in the tumor microenvironment. The purposes of our research were to examine the role of thrombocytosis in inflammatory breast cancer (IBC) and to know which cytokine drives thrombocytosis. METHODS:We reviewed the medical records o...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4463-6

    authors: Harano K,Kogawa T,Wu J,Yuan Y,Cohen EN,Lim B,Reuben JM,Ueno NT

    更新日期:2017-12-01 00:00:00